



RECEIVED

JUN 14 2001

TECH CENTER 1600/2900

DOCKET NO.: 0769-0420-0X PCT

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231



ATTORNEYS AT LAW

NORMAN F. OBLON  
(703) 413-3000  
NOBLON@OBLON.COM

KIRSTEN A. GRUENEBERG, PH. D.  
(703) 413-3000  
KGRUENEBERG@OBLON.COM

Re: Serial No.: 09/530,965  
Date Filed: MAY 18, 2000  
Applicants: Martha A. WARPEHOSKI, et al.  
For: ALPHA-HYDROXY, -AMINO AND  
-FLUORO DERIVATIVES OF BETA-  
SULPHONYL HYDROXAMIC ACIDS AS  
MATRIX METALLOPROTEINASES  
INHIBITORS  
Examiner: H. LIU  
GAU: 1624

SIR:

Attached hereto for filing are the following papers:

**1. RESPONSE TO RESTRICTION REQUIREMENT**

Our check in the amount of \$-0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. §1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. §1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Kirsten A. Grueneberg, Ph.D.  
Registration No. 47,297

Tel.: 703-413-3000  
Fax: 703-413-2220

NFO:KAG:ksh  
I:\user\KGRUN\07690420-ShrtCvr.wpd



22850



RECEIVED

JUN 14 2001

TECH CENTER 1600/2900

DOCKET NO.: 0769-0420-0X PCT

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

#8

IN RE APPLICATION OF: :  
MARTHA A. WARPEHOSKI ET AL : GROUP ART UNIT: 1624  
SERIAL NO.: 09/530,965 :  
FILED: MAY 18, 2001 : EXAMINER: H. LIU

FOR: ALPHA-HYDROXY,-AMINO AND  
-FLUORO DERIVATIVES OF BETA-  
SULPHONYL HYDROXAMIC ACIDS AS  
MATRIX METALLOPROTEINASES INHIBITORS

**RESPONSE TO RESTRICTION REQUIREMENT**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated May 11, 2001, Applicants elect, with  
traverse, Group II, Claims 4 and 6, for further prosecution.

**REMARKS**

The Office has required restriction in the present application as follows:

Group I: Claims 1-3, 5 and 7-19, drawn to the compounds of formula I, their  
compositions, and methods of use of the compounds; and

Group II: Claims 4 and 6, drawn to the compounds of formula 8.

Applicants elect, with traverse, Group II, Claim 4 and 6, for further prosecution.

The Examiner, citing PCT Rule 13.1 and 13.2, contends that Groups I-II do not relate  
to a single general inventive concept because they lack the same or corresponding special  
technical features. Specifically, the Office argues that the application lacks unity of